What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.

OIS Podcast | Ophthalmology's leading Podcast

English - March 21, 2019 04:00 - 22 minutes - 10.3 MB - ★★★★★ - 30 ratings
Investing Business Health & Fitness ophthalmology investment venture capital entrepreneurs oftalmólogo ophthalmic key opinion leader seco ascrs aao Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Wall Street Analyst David Nierengarten of Wedbush Dissects Recent Gene Therapy Shopping Spree

Next Episode: Novaliq’s Bernhard Günther Reveals Company’s Fateful Start, Promising Future for Dry Eye Treatments

We dip into the gene therapy pool one more time, talking with Jay Duker, MD about Luxturna’s impact on ophthalmology. We also discuss how the acquisitions of Spark and Nightstar are benefiting earlier-stage gene therapy start-ups, including his own Hemera Biosciences.